期刊文献+

ERK1/2通路与舌鳞癌细胞Cal-27生物学行为的相关性 被引量:4

Relationships between ERK1/2 Signaling Pathway and Biological Behaviors of TSCC Cal-27 Cells
下载PDF
导出
摘要 目的探讨ERK1/2通路对人舌鳞癌Cal-27细胞生物学行为的影响。方法不同浓度ERK1/2通路抑制剂U0126(5、10、20、40μmol/L)作用于Cal-27,分别处理12、24、36、48h。然后用MTT法检测U0126对Cal-27细胞增殖的影响,划痕实验和Transwell小室法分别检测其对Cal-27体外迁移和侵袭的影响,流式细胞术检测其对细胞凋亡和细胞周期的影响。结果不同浓度U0126均能抑制Cal-27的增殖(P<0.05),减弱Cal-27的迁移和侵袭能力(P<0.05);并能诱导细胞凋亡,使S和G2/M期肿瘤细胞比例减少,G0/G1期比例增加(P<0.05)。结论 U0126能通过抑制ERK1/2信号通路,诱导肿瘤细胞凋亡,抑制细胞的增殖、迁移和侵袭,提示ERK1/2信号通路可能是治疗人类恶性肿瘤的一个潜在的靶点。 Objective To investigate the effects of U0126 on the biological behaviors of squamous cell carcinoma of the tongue(TSCC)Cal-27 cells.Methods The Cal-27 cells were treated with different concentrations of U0126(5,10,20 and 40 μmol/L)for 12,24,36 and 48 h.The effect of U0126 on proliferation of Cal-27 cells was measured by using MTT assay.Scratch wound assay and Transwell were used to detect the influence of U0126 on migration and invasion of Cal-27 cells in vitro.Flow cytometry was used to detect cell cycle and apoptosis.Results Different concentrations of U0126 could inhibit the proliferation of Cal-27 cells(P0.05),attenuate migration and invasion of tumor cells(P0.05)and induce apoptosis of tumor cells,decrease proportion of cells in S and G2/M phases and increase that in G0/G1 phase(P0.05).Conclusion U0126 can induce tumor cell apoptosis and inhibit cell proliferation,migration and invasion,suggesting that ERK1/2 pathway may be a potent therapeutic target for human cancer.
出处 《华中科技大学学报(医学版)》 CAS CSCD 北大核心 2012年第6期650-655,共6页 Acta Medicinae Universitatis Scientiae et Technologiae Huazhong
关键词 U0126 舌鳞状细胞癌 ERK1 2通路 迁移 侵袭 细胞凋亡 U0126 squamous cell carcinoma of the tongue ERK1/2 pathway migration invasion apoptosis
  • 相关文献

参考文献23

  • 1Kademani D. Oral cancer[J]. Mayo Clin Proc, 2007,82 (7), 878-887.
  • 2Kato Y, Tapping R I, Huang S, et al. Bmkl/Erk5 is required for cell proliferation induced by epidermal growth factor[J]. Nature,1998,395(6703) :713 716.
  • 3Malumbres M,Barbacid M. RAS oncogenes:the first 30 years [J]. Nat Rev Cancer,2003,3(6) :459-465.
  • 4Davies H,Bignell G R, Cox C, et al. Mutations of the BRAF gene in human cancer[J]. Nature,2002,:17(6892):949 954.
  • 5JemaI A, Siegel R, Ward E, et al. Cancer statistics, 2006[J]. CA Cancer J Clin, 2006,56 (2) : 106-130.
  • 6Han J,Lee J D,Bibbs L,et al. A MAP kinase targeted by en- dotoxin and hyperosmolarity in mammalian cells[J]. Science, 1994,265(5173) : 808-811.
  • 7Boulton T G,Nye S H,Robbins D J,et al. ERKs:a family of protein-serine/threonine kinases that are activated and tyro- sine phosphorylated in response to insulin and NGF[J]. Cell, 1991,65(4) :663-675.
  • 8Davis R J. The mitogen-activated protein kinase signal trans- duction pathway [J ]. J Biol Chem, 1993, 268 (20) : 14553- 14556.
  • 9Eastman A. Survival factors,intracellular signal transduetion, and the activation of endonueleases in apoptosis[J]. Semin Cancer Biol, 1995,6 (1) : 45-52.
  • 10Treisman R. Regulation of transcription by MAP kinase cas- cades[J]. Curt Opin Cell Biol, 1996,8(2) :205-215.

二级参考文献21

  • 1Stenzinger A, Schreiner D, Koch P, et al. Cell and molecular biology of the novel protein tyrosine-phosphatase-interacting protein 51[J]. Int Rev Cell Mol Biol, 2009,275 : 183-246.
  • 2Yu C, Han W,Shi T,et al. PTPIP51,a novel 14-3-3 binding protein,regulates cell morphology and motility via Raf-ERK pathway[J]. Cell Signal,2008,20(12) :2208-2220.
  • 3McCubrey J A, Steelman L S, Chappell W H, et al Roles of the Raf/MEK/ERK pathway in cell growth,malignant transformation and drug resistance[J]. Bioehim Biophys Acta, 2007,1773(8) : 1263-1284.
  • 4Xiang X, Zang M, Waelde C A, et al. Phosphorylation of 338SSYy341 regulates specific interaction between Raf-1 and MEK1[J]. J Biol Chem,2002,277(47):44996-45003.
  • 5Livak K J,Schmittgen T D. Analysis of relative gene expression data using real-time quantitative PCR and the 2-^△△ct method[J]. Methods,2001,25(4) 1402-408.
  • 6Landis S H, Murray T, Bolden S, et al. Cancer statics, 1999 [J]. CA Cancer J C1in,1999,49(1) :8-31.
  • 7Stenzinger A,Kajosch T,Tag C, et al. The novel protein PT- PIP51 exhibits tissue- and cell-specific expression[J]. Histochem Cell Biol,2005,123(1):19-28.
  • 8Stenzinger A, Marker D, Koch P, et aI. Protein tyrosine phosphatase interacting protein 51 (PTPIP51) mRNA expression and localization and its in vitro interacting partner protein tyrosine phosphatase IB(PTPIB)in human placenta of the first,second, and third trimester[J]. Histochem Cytochem, 2009,57(2) : 143-153.
  • 9Dent P, Yacoub A, Fisher P B,et al. MAPK pathways in radiation responses[J]. Oncogene,2003,22(37) :5885-5896.
  • 10Tidyman W E,Rauen K A. The RASopathies:developmental syndromes of Ras/MAPK pathway dysregulation[J]. Curr Opin Genet Dev, 2009,19(3) : 230-236.

共引文献4

同被引文献29

  • 1Apaporn Menakongka,Tuangporn Suthiphongchai.Involvement of PI3K and ERK1/2 pathways in hepatocyte growth factor-induced cholangiocarcinoma cell invasion[J].World Journal of Gastroenterology,2010,16(6):713-722. 被引量:33
  • 2艾星,张旭,吴准,马鑫,居正华,王保军,史涛坪.Expression of KAI1/CD82 and MRP-1/CD9 in Transitional Cell Carcinoma of Bladder[J].Journal of Huazhong University of Science and Technology(Medical Sciences),2007,27(1):79-82. 被引量:7
  • 3Grgic I, Duffield d S, Humphrcys B D. The origin of intersti tial myofibroblasts in chronic kidney disease [J]. Pediatric Nephrology,2011,27(2) :183 193.
  • 4Wiwanitkit V. Fibrosis and evidm:ce for epithelial-mesenchy- mal transition in the kidneys of patients with staghorn calculi [J]. BJU lnt,2011,108(8) :1aa6-1845.
  • 5Zeisberg E M, Potenta S E, Sugimoto H. et al. Fibroblasts in kidney fibrosis emerge via endothelial-to-mesenehymal transi tion [J]. J Am Soc Nephrol,2008,19(12) :2282 2287.
  • 6Li J, Qu X, Bertram J F. Endothelial-myofibroblast transition contributes to the early development of diabetic renal intersti tial fibrosis in streptozotocin-induced diabetic mice[J]. Am J Pathol,2009,175(4) :1380 1388.
  • 7Basile DP,Friedrich J L, Spahic J, et al. Impaired endothelial proliferation and mesenchymal transition contribute to vascu- lar rare faction following acute kidney injury[J] Am J Physi ol Renal Physiol,2011,300(3) :7:1-733.
  • 8L6pez-Novoa J M,Nieto M A. Inflammation and EMT:an al- liance towards organ fibrosis and cancer progression [J]. Mol Med, 2009,1 (6) : 303-314.
  • 9Medici D, Potenta S, Kalluri R. Transforming growth factor- :z promotes Snail mediated endothelial mesenchymal transi- tionthrough convergence of Sma&dependent and Smad-inde- pendentsignaling[J]. Biochem J, 2011,437 (3) : 515-520.
  • 10Chen Y,Leask A,Abraham D J,et al. Thrombospondin 1 is a key mediator of tranforming growth factor D-mediated cell contractility in systemic sclerosis via a mitogen activated protein kinase kinase(MEK)/extracellular signal- regulated kinase(ERK)-dependent mechanism[J]. Fibrogenesis Tissue Repair,2011,4(l) :9.

引证文献4

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部